+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-04-17Number of Pages: 192

Pharmerging Market (Product Type - Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics, and OTC Drugs) and Healthcare (Medical Devices, Diagnostic Instruments, and IT and Record Management); Economic Growth Levels - Tier - 1, Tier - 2, and Tier - 3; Indications - Lifestyle Diseases, Cancer and Autoimmune Diseases, and Infectious Diseases; Distribution Channel - Hospitals, Clinics, Retail Pharmacies, E-commerce, and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Pharmerging Market: Snapshot

The global pharmerging market is experiencing a significant rise, especially in the emerging economies across the world. The rising prevalence of non-communicable diseases, aging population, increasing life expectancy, escalating income, surging government expenditure on health care, free trade agreement, and the constant research and development are some of the key factors behind the growth of this market.

With the increasing incidence rate of various diseases, the demand for highly innovative and better outcome products is also increasing, which is likely to result in a substantial growth of this market in the future. The continual innovation and advancements in the drugs for the treatment of a host of diseases are also anticipated to drive this market over the next few years. The global market for pharmerging, which stood at US$552.8 mn in 2015, is expected to rise at a CAGR of 11.30% between 2016 and 2024 and reach a value of US$1.40 bn by the end of 2024.

pharmerging market

Pharmaceutical Products to Witness Strong Growth in Near Future

On the basis of type of product, pharmaceuticals and healthcare are the two main segments of the global market for pharmerging. The pharmaceuticals segment dominated the overall market in 2016 with a share of 65.2%. The scenario is expected to continue like this over the next few years, thanks to the significant rise in the demand for both, the branded as well as generic drugs.

Apart from this, the increasing number of innovative therapies for the treatment of various diseases at affordable price is also projected to boost this segment in the years to come. On the other hand, the healthcare segment is likely to be driven by the growing emphasis on medical devices used in the diagnosis and treatment of a number of diseases.

Based on the indication, the worldwide market for pharmerging has been classified into lifestyle diseases, cancers and autoimmune diseases, and infectious diseases. Among these, lifestyle-borne and cancer and autoimmune diseases are projected to offer lucrative opportunities for the growth of this market with attractiveness index over the forthcoming years.

Asia Pacific to Remain on Top

In terms of the geography, the global pharmerging market reports its presence across Latin America, the Middle East and Africa, Asia Pacific, North America, and Europe. With a share of 53%, Asia Pacific led this market in 2016. Researchers expect this regional market to remain on the top, thanks to rapid urbanization, increasing patent expiration, and the surge in the investments for medical research. China has emerged as the key domestic market for pharmerging in Asia Pacific.

Among other regional markets for pharmerging, Europe and Latin America are likely to witness healthy growth in the near future. Technological advancements, extensive research and development practices, and the increasing awareness regarding the treatment and the management of healthcare facilities are likely to propel the Latin America market. The Europe market is predicted to be drive by the large population size, growing disease prevalence, and the increasing health expenditure in the region.

Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Tata Consultancy Services Ltd., LUPIN, GlaxoSmithKline Plc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Merck & Co. Inc. F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., and Abbott Laboratories are the leading players in the global pharmerging market.

Section 01 Preface 
1.1. Report Scope and Market Segmentation 
1.2. Research Highlights

Section 02 Assumptions and Research Methodology 
2.1. Assumptions and Acronyms Used
2.3. Research Methodology

Section 03 Executive Summary
3.1. Global Pharmerging Market Snapshot

Section 04 Market Overview
4.1. Product Overview
4.2. Key Industry Developments

Section 05 Market Dynamics
5.1. Opportunity Analysis
5.2. Drivers and Restraints Snapshot Analysis
5.3. Drivers
       5.3.1. Continuous Research and Development
       5.3.2. Increasing Government Expenditure on Healthcare
       5.3.3. Rising non-communicable diseases (NCDs)
       5.3.4. Free trade agreement
       5.3.5. Growing income
       5.3.6. Aging population and increasing life expectancy
5.4. Restraints
       5.4.1. Economic challenges in Africa
       5.4.2. Weak or ambiguous patent laws
       5.4.3. Growing medical tourism
       5.4.4. Partnerships and acquisition of local players by MNCs
5.5. Porter’s Analysis
5.6. Value Chain Analysis (Medical Devices)
5.7. Value Chain Analysis (Pharmaceuticals)
5.8. Mergers and Acquisitions Landscape
5.9. Reimbursement Scenario
5.10. Pharmerging Market Outlook

Section 06 Global Pharmerging Market Analysis, by Product Type
6.1. Key Findings
6.2. Introduction
6.3. Market Forecast by Product Type
       6.3.1. Pharmaceuticals
                6.3.1.1. Branded Prescription Drugs
                6.3.1.2. Generic Drugs
                           6.3.1.2.1. Branded Generic
                           6.3.1.2.2. Unbranded Generic
                6.3.1.3. OTC Drugs
       6.3.2. Healthcare
                6.3.2.1. Medical Devices
                6.3.2.2. In Vitro Diagnostic
                6.3.2.3. Others (IT and record management)
6.4. Global Pharmerging Market Attractiveness Analysis, by Product Type
6.3. Key Trends

Section 07 Global Pharmerging Market Analysis, by Indications
7.1. Key Findings
7.2. Introduction
7.3. Market Forecast by Indications
       7.3.1. Lifestyle Diseases
       7.3.2. Cancers & Autoimmune diseases
       7.3.3. Infectious diseases
       7.3.4. Others
7.4. Global Pharmerging Market Attractiveness Analysis, by Indications

Section 08 Global Pharmerging Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Forecast by Distribution Channel
       8.3.1. Hospitals
       8.3.2. Clinics
       8.3.3. Retail Pharmacies
       8.3.4. E-commerce
       8.3.5. Drug Stores
8.4. Global Pharmerging Market Attractiveness Analysis, by Distribution Channel
8.5. Key Trends

Section 09 Global Pharmerging Market Analysis, by Economic Growth Levels
9.1. Key Findings
9.2. Introduction
9.3. Market Forecast by Economic Growth Levels
       9.3.1. Tier-1
       9.3.2. Tier-2
       9.3.3. Tier-3
9.4. Global Pharmerging Market Attractiveness Analysis, by Economic Growth Levels

Section 10 Global Pharmerging Market Analysis, by Region 
10.1. Global Market Scenario, by Country
10.2. Global Pharmerging Market Value Share Analysis and Market Attractiveness Analysis, by Region
       10.2.1. Market Forecast by Region
       10.2.2. Latin America
       10.2.3. Asia Pacific
       10.2.4. Europe
       10.2.5. Middle East & Africa

Section 11 Latin America Pharmerging Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Latin America Pharmerging Market Value Share Analysis, by Country
11.4. Latin America Pharmerging Market Forecast, by Country
11.5. Latin America Pharmerging Market Value Share Analysis, by Product Type
11.6. Latin America Pharmerging Market Forecast, by Product Type
11.7. Latin America Pharmerging Market Value Share Analysis, by Indications
11.8. Latin America Pharmerging Market Forecast, by Indications
11.9. Latin America Pharmerging Market Value Share Analysis, by Distribution Channel
11.10. Latin America Pharmerging Market Forecast, by Distribution Channel
11.11. Latin America Pharmerging Market Attractiveness Analysis

Section 12 Asia Pacific Pharmerging Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Asia Pacific Pharmerging Market Value Share Analysis, by Country
12.4. Asia Pacific Pharmerging Market Forecast, by Country
12.5. Asia Pacific Pharmerging Market Value Share Analysis, by Product Type
12.6. Asia Pacific Pharmerging Market Forecast, by Product Type
12.7. Asia Pacific Pharmerging Market Value Share Analysis, by Indications
12.8. Asia Pacific Pharmerging Market Forecast, by Indications
12.9. Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Pharmerging Market Forecast, by Distribution Channel
12.11. Asia Pacific Pharmerging Market Attractiveness Analysis

Section 13 Europe Pharmerging Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Europe Pharmerging Market Value Share Analysis, by Country
13.4. Europe Pharmerging Market Forecast, by Country
13.5. Europe Pharmerging Market Value Share Analysis, by Product Type
13.6. Europe Pharmerging Market Forecast, by Product Type
13.7. Europe Pharmerging Market Value Share Analysis, by Indications
13.8. Europe Pharmerging Market Forecast, by Indications
13.9. Europe Pharmerging Market Value Share Analysis, by Distribution Channel
13.10. Europe Pharmerging Market Forecast, by Distribution Channel
13.11. Europe Pharmerging Market Attractiveness Analysis

Section 14 Middle East & Africa Pharmerging Market Analysis
14.1. Key Findings
14.2. Market Overview
14.3. Middle East & Africa Pharmerging Market Value Share Analysis, by Country
14.4. Middle East & Africa Pharmerging Market Forecast, by Country
14.5. Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type
14.6. Middle East & Africa Pharmerging Market Forecast, by Product Type
14.7. Middle East & Africa Pharmerging Market Value Share Analysis, by Indications
14.8. Middle East & Africa Pharmerging Market Forecast, by Indications
14.9. Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel
14.10.    Middle East & Africa Pharmerging Market Forecast, by Distribution Channel
14.11.    Middle East & Africa Pharmerging Market Attractiveness Analysis

Section 15 Competition Landscape
15.1. Competition Matrix
15.2. Pharmerging Market Share Analysis by Company, 2016
15.3. Company Profiles
       15.3.1 Abbott Laboratories
                15.3.1.1 Financial Overview
                15.3.1.2. Product Portfolio
                15.3.1.3. Business Strategies
                15.3.1.4. Recent Developments
       15.3.2 Koninklijke Philips N.V.
                15.3.2.1 Financial Overview
                15.3.2.2. Product Portfolio
                15.3.2.3. Business Strategies
                15.3.2.4. Recent Developments
       15.3.3 F. Hoffmann-La Roche Ltd.
                15.3.3.1 Financial Overview
                15.3.3.2. Product Portfolio
                15.3.3.3. Business Strategies
                15.3.3.4. Recent Developments
       15.3.4. Merck & Co., Inc.
                15.3.4.1 Financial Overview
                15.3.4.2. Product Portfolio
                15.3.4.3. Business Strategies
                15.3.4.4. Recent Developments
       15.3.5 Novartis AG
                15.3.5.1 Financial Overview
                15.3.5.2. Product Portfolio
                15.3.5.3. Business Strategies
                15.3.5.4. Recent Developments
       15.3.6 Johnson & Johnson
                15.3.6.1 Financial Overview
                15.3.6.2. Product Portfolio
                15.3.6.3. Business Strategies
                15.3.6.4. Recent Developments
       15.3.7 Teva Pharmaceutical Industries Ltd.
                15.3.7.1 Financial Overview
                15.3.7.2. Product Portfolio
                15.3.7.3. Business Strategies
                15.3.7.4. Recent Developments
       15.3.8. AstraZeneca
                15.3.8.1 Financial Overview
                15.3.8.2. Product Portfolio
                15.3.8.3. Business Strategies
                15.3.8.4. Recent Developments
       15.3.9. GlaxoSmithKline plc.
                15.3.9.1 Financial Overview
                15.3.9.2. Product Portfolio
                15.3.9.3. Business Strategies
                15.3.9.4. Recent Developments
       15.3.10. LUPIN
                15.3.10.1 Financial Overview
                15.3.10.2. Product Portfolio
                15.3.10.3. Business Strategies
                15.3.10.4. Recent Developments
       15.3.11. Tata Consultancy Services Limited
                15.3.11.1 Financial Overview
                15.3.11.2. Product Portfolio
                15.3.11.3. Business Strategies
                15.3.11.4. Recent Developments
       15.3.12. Sun Pharmaceutical Industries Ltd
                15.3.12.1 Financial Overview
                15.3.12.2. Product Portfolio
                15.3.12.3. Business Strategies
                15.3.12.4. Recent Developments
       15.3.13. Huadong Medicine Co., Ltd
                15.3.13.1 Financial Overview
                15.3.13.2. Product Portfolio
                15.3.13.3. Business Strategies
                15.3.13.4. Recent Developments

List of Figures

Figure 01: Market Value Share, by Product type (pharmaceuticals) (2016) Revenue (US$ Bn)
Figure 02: Market Value Share, by Product type (health care) (2016) Revenue (US$ Bn)
Figure 03: Market Value Share (US$ Bn), by Indications, (2016)
Figure 04: Market Value Share (US$ Bn), by Distribution Channel, (2016)
Figure 05: Global Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 06: Global Pharmerging Market Revenue (US$ Bn) and Y-o-Y Growth (%) - Pharmaceuticals, 2015–2025
Figure 07: Global Pharmerging Market Revenue (US$ Bn) and Y-o-Y Growth (%) - Health Care, 2015–2025
Figure 08: Global Branded Prescription Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 09: Global Generic Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 10: Global OTC Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Global Medical Devices Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 12: Global In Vitro Diagnostics Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–    2025
Figure 13: Global Pharmerging Market Revenue (US$ Bn) and Y-o-Y Growth (%) - Others (IT and Record Management), 2015–2025
Figure 14: Global Pharmerging Market Attractiveness Analysis, by Product Type, 2015–2025
Figure 15: highlights market share, CAGR, and absolute growth index of the global pharmerging market by product type
Figure 16: Global Pharmerging- Lifestyle Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 17: Global Pharmerging - Cancers and Autoimmune Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 18: Global Pharmerging - Infectious Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 19: Global Pharmerging Other Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 20: Pharmerging Market Attractiveness Analysis, by Indications, 2015–2025
Figure 21: Global Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 22: Global Pharmerging - Hospitals Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 23: Global Pharmerging - Clinics Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–    2025
Figure 24: Global Pharmerging - Retail Pharmacies Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 25: Global Pharmerging - E-commerce Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 26: Global Pharmerging - Drug Stores Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
Figure 27: Poultry Pharmaceuticals Market Attractiveness Analysis, by Distribution Channel, 2015–2025
Figure 28: Global Pharmerging Market Value Share Analysis, by Economic Growth Levels, 2017 and 2025
Figure 29: Global Pharmerging- Tier-1 Market Revenue (US$ Bn), 2015–2025
Figure 30: Global Pharmerging - Tier-2 Market Revenue (US$ Bn), 2015–2025
Figure 31: Global Pharmerging - Tier-3 Market Revenue (US$ Bn), 2015–2025
Figure 32: Pharmerging Market Attractiveness Analysis, by Economic Growth Levels, 2015-2025
Figure 33: Global Pharmerging Market Value Share Analysis, by Region, 2016 and 2025
Figure 34: Global Animal Blood Plasma Products and Derivatives Market Attractiveness Analysis, by Region, 2015–2025
Figure 35: Latin America Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 36: Latin America Pharmerging Market Attractiveness Analysis, by Country, 2017–2025
Figure 37: Latin America Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
Figure 38: Latin America Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 39: Latin America Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
Figure 40: Latin America Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 41: Latin America Pharmerging Market Attractiveness Analysis, by Product Type, 2017–    2025
Figure 42: Latin America Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025
Figure 43: Latin America Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 44: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2015-    2025
Figure 45: Asia Pacific Pharmerging Market Attractiveness Analysis, by Country, 2017-2025
Figure 46: Asia Pacific Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
Figure 47: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 48: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type – Pharmaceuticals, 2016 and 2025
Figure 49: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type - Healthcare, 2016 and 2025
Figure 50: Asia Pacific Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
Figure 51: Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channels, 2016 and 2025
Figure 52: Asia Pacific Pharmerging Market Attractiveness Analysis, by Product Type, 2017–2025 
Figure 53: Asia Pacific Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025 
Figure 54: Asia Pacific Pharmerging Market Attractiveness Analysis, by Distribution Channels, 2017–2025 
Figure 55: Europe Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 56: Europe Pharmerging Market Attractiveness Analysis, by Country, 2017–2025
Figure 57: Europe Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
Figure 58: Europe Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 59: Europe Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
Figure 60: Europe Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 61: Europe Pharmerging Market Attractiveness Analysis, by Product Type, 2017–2025
Figure 62: Europe Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025
Figure 63: Europe Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 64: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 20152025
Figure 65: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Country, 2017–2025
Figure 66: Middle East & Africa Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
Figure 67: Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 68: Middle East & Africa Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
Figure 69: Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 70: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Product Type, 2017–2025
Figure 71: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025
Figure 72: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 73: Global Pharmaceutical Market Share Analysis by Company, 2016 (Estimated)
Figure 74: Global Medical Device Market Share Analysis by Company 2016 (Estimated)

 

List of Tables 

Table 01: Global Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
Table 02: Global Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
Table 03: Global Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–2025
Table 04: Global Pharmerging Market Size (US$ Bn) Forecast, by Health Care, 2015–2025
Table 05: Global Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
Table 06: Global Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
Table 07: Global Pharmerging Market Size (US$ Bn) Forecast, by Economic Growth Levels, 2017–2025 
Table 08: Global Pharmerging Market Size (US$ Bn) Forecast, by Region, 2015–2025
Table 09: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025
Table 10: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
Table 11: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
Table 12: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–2025
Table 13: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Health Care, 2015–2025
Table 14: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
Table 15: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
Table 16: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025 
Table 17: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015-2025
Table 18: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type - Pharmaceuticals, 2015-2025
Table 19: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type – Pharmaceutical Generic Drugs, 2015-2025
Table 20: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type - Healthcare, 2015-2025
Table 21: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015-    2025
Table 22: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channels, 2015-2025
Table 23: Europe Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025
Table 24: Europe Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–    2025
Table 25: Europe Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
Table 26: Europe Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–    2025
Table 27: Europe Pharmerging Market Size (US$ Bn) Forecast, by Health Care Product, 2015–2025
Table 28: Europe Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
Table 29: Europe Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
Table 30: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025
Table 31: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
Table 32: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
Table 33: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–2025
Table 34: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Health Care Product, 2015–2025
Table 35: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
Table 36: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025

Global Pharmerging Market: Overview

This report on pharmerging market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pharmaceutical products as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pharmerging market with respect to the leading market segments based on major products, applications and geographies.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pharmerging market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/materials/technologies/end-users/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.

Global Pharmerging Market: Segmentation

The global pharmerging market is divided into: by product, by economic growth levels, by distribution channel and by geography. Product type segment of pharmerging market was divided into Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics), and OTC Drugs) and Healthcare (Medical Devices, and Diagnostic Instruments, Others (IT and record management)). On the basis of Economic Growth Levels the market was divided as - Tier – 1, Tier – 2 and Tier – 3). On the basis of distribution channel the pharmerging market is divided as hospitals, clinics, retail pharmacies, e-commerce, and drug stores.

The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and market volume in terms of units for the period from 2016 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2016 as the base year.

Geographically, the pharmerging market has been segmented into five regions: North America, Europe, Asia Pacific, Europe, Middle East & Africa (MEA), and Latin America. Each regional market for pharmerging market has been further categorized into major product, applications, material, and end-user segments considered within the scope of the study. Key country (U.S., Canada, Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn and volume in terms of units for the period from 2014 to 2025 along with CAGR % from 2016 to 2025 are provided for all the regions and nations considering 2016 as the base year.

Companies Mentioned in the Research Report

The report profiles key manufacturers in the pharmerging market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc., LUPIN, Tata Consultancy Services Limited, Sun Pharmaceutical Industries Ltd., Huadong Medicine Co., Ltd., etc.

The global pharmerging Market has been segmented as follows:

By Product Type

  • Pharmaceuticals
    • Branded Prescription Drugs
    • Generic Drugs
      • Branded Generics
      • Unbranded Generics
    • OTC Drugs
  • Healthcare
    • Medical Devices
    • Diagnostic Instruments
    • Others (IT and record management)

By Indications

  • Lifestyle Diseases
  • Cancer and autoimmune diseases
  • Infectious Diseases
  • Others

By Distribution Channel

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • E-commerce
  • Drug Stores

By Region

  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa


 
 
Back To Top